Insights

Why Repligen Is Up More Than 10% Today

What happened
Shares of biotech company Repligen (NASDAQ: RGEN) are up an impressive 10.1% as of 11:15 a.m. ET Wednesday, according to data from S&P Global Market Intelligence. The rally is in response to the release of quarterly sales and earnings figures that both topped analysts’ expectations.
So what
For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share. Organic revenue was up 44% year over year, while profits improved 35% compared to the year-ago operating bottom line of $0.68 per share. Analysts were only calling for sales of $185.5 million and earnings of $0.72 per share.

Image source: Getty Images.

Strength from its gene therapy, filtration, and chromatography arms accounts for most of that growth, although COVID-related revenue still makes up roughly one-fourth of the company’s business…a business Repligen’s management knows is slowing. Revenue guidance for the full year was dialed back from a range of $800 million to $830 million to a range of only $770 million to $800 million. Income guidance was similarly adjusted, with Repligen Corporation now looking for a 2022 operating bottom line of between $3.07 and $3.15 per share. The analyst community had been modeling an average of $3.25.
All of those numbers, however, are still markedly better than last year’s.
Now what
On the surface, the contracted guidance makes the glass seem half empty rather than half full. Yet, investors are clearly celebrating the first-quarter results and the outlook for the remainder of the year. What gives?
The bulk of today’s strength can be attributed to the idea that the market was quietly, subconsciously planning for a much weaker report. The stock’s price had been more than cut in half between September’s high and Tuesday’s close, when it reached a new 52-week low. Wednesday’s report suggests much of that worry wasn’t merited.
More to the point, while today’s surge may be a tough move to follow, it could be interpreted as a sign that this biotech stock’s sell-off is done and a new bullish paradigm is taking shape. In this vein, the consensus price target for Repligen shares still stands at $272.63, up more than 70% from today’s sharply elevated price.
James Brumley has no position in any of the stocks mentioned. The Motley Fool owns and recommends Repligen. The Motley Fool has a disclosure policy. –

What happened

Shares of biotech company Repligen (NASDAQ: RGEN) are up an impressive 10.1% as of 11:15 a.m. ET Wednesday, according to data from S&P Global Market Intelligence. The rally is in response to the release of quarterly sales and earnings figures that both topped analysts’ expectations.

So what

For the three-month stretch ending in March, Repligen Corporation turned record-breaking revenue of $206.4 million into operating earnings of $0.92 per share. Organic revenue was up 44% year over year, while profits improved 35% compared to the year-ago operating bottom line of $0.68 per share. Analysts were only calling for sales of $185.5 million and earnings of $0.72 per share.

Image source: Getty Images.

Strength from its gene therapy, filtration, and chromatography arms accounts for most of that growth, although COVID-related revenue still makes up roughly one-fourth of the company’s business…a business Repligen’s management knows is slowing. Revenue guidance for the full year was dialed back from a range of $800 million to $830 million to a range of only $770 million to $800 million. Income guidance was similarly adjusted, with Repligen Corporation now looking for a 2022 operating bottom line of between $3.07 and $3.15 per share. The analyst community had been modeling an average of $3.25.

All of those numbers, however, are still markedly better than last year’s.

Now what

On the surface, the contracted guidance makes the glass seem half empty rather than half full. Yet, investors are clearly celebrating the first-quarter results and the outlook for the remainder of the year. What gives?

The bulk of today’s strength can be attributed to the idea that the market was quietly, subconsciously planning for a much weaker report. The stock’s price had been more than cut in half between September’s high and Tuesday’s close, when it reached a new 52-week low. Wednesday’s report suggests much of that worry wasn’t merited.

More to the point, while today’s surge may be a tough move to follow, it could be interpreted as a sign that this biotech stock’s sell-off is done and a new bullish paradigm is taking shape. In this vein, the consensus price target for Repligen shares still stands at $272.63, up more than 70% from today’s sharply elevated price.

James Brumley has no position in any of the stocks mentioned. The Motley Fool owns and recommends Repligen. The Motley Fool has a disclosure policy.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

  • This field is for validation purposes and should be left unchanged.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US & HK* Trades. Click Here!